JNJ - Johnson & Johnson

NYSE - Nasdaq Real Time Price. Currency in USD
137.76
-0.68 (-0.49%)
As of 2:11PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close138.44
Open138.33
Bid137.09 x 1300
Ask137.11 x 1100
Day's Range136.65 - 138.50
52 Week Range118.62 - 148.99
Volume2,362,183
Avg. Volume7,709,751
Market Cap366.823B
Beta (3Y Monthly)0.66
PE Ratio (TTM)24.57
EPS (TTM)5.61
Earnings DateApr 16, 2019
Forward Dividend & Yield3.60 (2.62%)
Ex-Dividend Date2019-02-25
1y Target Est144.71
Trade prices are not sourced from all markets
  • Bayer Stock Tumbles After Jury Finds Weed-Killer Roundup Caused Cancer
    Investor's Business Daily1 hour ago

    Bayer Stock Tumbles After Jury Finds Weed-Killer Roundup Caused Cancer

    Germany's Bayer's market cap shrank by $7 billion Wednesday after a California jury found its Roundup weed killer caused cancer. Now, the jury must determine liabilities and damages.

  • Reuters3 hours ago

    US STOCKS-FedEx outlook weighs on Wall St ahead of Fed policy decision

    U.S. stocks fell on Wednesday after economic bellwether FedEx Corp's downbeat profit outlook raised concerns about global growth, while investors waited for more clarity on the Federal Reserve's interest rate forecasts for the rest of the year. The policy statement will also shed light on long-awaited details regarding the Fed's plans to stop reducing its holdings of Treasury bonds. "With the Fed, investors will be focusing on the growth outlook for 2019.

  • AbbVie's Venclexta Multiple Myeloma Studies Put on Hold by FDA
    Zacks3 hours ago

    AbbVie's Venclexta Multiple Myeloma Studies Put on Hold by FDA

    FDA places a partial clinical hold on all studies evaluating AbbVie's (ABBV) Venclexta (venetoclax) for the treatment of multiple myeloma.

  • Reuters4 hours ago

    US STOCKS-Wall St drops after weak FedEx outlook; Fed on tap

    U.S. stocks fell on Wednesday after economic bellwether FedEx issued a downbeat profit outlook and as investors waited for more clarity on the Federal Reserve's interest rate forecasts for the rest of the year. The policy statement will also shed light on long-awaited details regarding the Fed's plans to stop reducing its holdings of Treasury bonds. Hopes of a dovish stance from the Fed hit the rate-sensitive financial stocks, which fell 0.35 percent, while the bank subsector slipped 0.28 percent.

  • Stocks making the biggest moves premarket: General Mills, Johnson & Johnson, Viacom, Sony & more
    CNBC6 hours ago

    Stocks making the biggest moves premarket: General Mills, Johnson & Johnson, Viacom, Sony & more

    These are the stocks posting the largest moves before the bell.

  • 3 Dividend Stocks Ideal for Retirees
    Motley Fool17 hours ago

    3 Dividend Stocks Ideal for Retirees

    These two popular dividend stocks, and one you've probably never heard of, should fit a retiree's portfolio.

  • Analysts Are Divided on Johnson & Johnson Stock
    Market Realist23 hours ago

    Analysts Are Divided on Johnson & Johnson Stock

    How Major Pharmaceutical Stocks Are Positioned This Month(Continued from Prior Part)Analysts’ recommendations and target priceWall Street analysts have given Johnson & Johnson (JNJ) a 12-month consensus target price of $144.71, 5.50% higher

  • Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
    PR Newswireyesterday

    Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

    The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of the webcast will be available approximately three hours after the conference call concludes.

  • Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know
    Zacks2 days ago

    Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know

    Johnson & Johnson (JNJ) closed the most recent trading day at $137.35, moving -0.19% from the previous trading session.

  • 3 Consumer Staples Stocks to Trade in 2019
    InvestorPlace2 days ago

    3 Consumer Staples Stocks to Trade in 2019

    So far in 2019, the bulls have been in complete control over the stock market. This strength comes despite there not yet being a resolution to the global tariff war and while we await the conclusion of Brexit. However, when things go south for stocks the breakdown comes fast and portfolios suffer severe consequences if investors didn't balance them properly -- that brings us to consumer staples stocks.Some sectors are better at withstanding selling pressure than others. During a selloff, momentum stocks like Amazon (NASDAQ:AMZN) and Chipotle (NYSE:CMG) likely fall much faster than older, dividend-paying stocks. When times are tough, consumer stocks hold their value much better than most others.So why isn't everyone only in consumer staples stocks? Because what makes them almost bullet proof on the way down also slows them down during rallies. Traders are now on an upswing, so consumer stocks are generally lagging.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBut therein lies the opportunity.This year, the Consumer Staples Select Sector SPDR ETF (NYSEARCA:XLP) is up only half as much as the S&P 500. So if the bulls remain in control for the next two weeks, consumer staple stocks will have the opportunity of a catch-up rally.Furthermore, they're worth snatching up because there are tremendous risks that still loom over the global business sentiment. Yes, stocks are rising now but most of the risks that caused the selling last year are still here. Only the threat from a combative U.S. Fed has abated. So if the sellers come back online, then the consumer staple investments will hold up better than the general markets, so they are a safer bet. * 10 Dividend Stock Winners These three consumer stocks stand out in the sector: Mondelez International (NASDAQ:MDLZ), Johnson & Johnson (NYSE:JNJ) and the Consumer Staples ETF (NYSEARCA:XLP). Here's more about each. Mondelez (MDLZ)Source: Shutterstock Mondelez made news last year as it invested $4 billion into Canopy Growth (NASDAQ:CGC), which quickly became a go-to cannabis stock to own (it had the best balance sheet of them all). So clearly, MDLZ is a company that is not afraid to take risks. And if the hype of the potential revenues from pot-related products and services is actually true, then MDLZ will get a handsome return on its investment.Meanwhile, MDLZ stock has its own reasons for ownership. It is now trading above the zone around $45.50, which has been resistance for years. So now it has solid footing below to attack the all-time highs. About a month ago it almost broke out of them, so it could be reloading to set new highs soon. If the geopolitical headlines comply, MDLZ stock should blaze a new trail soon. As long as it's above $45 per share, this is a real possibility.MDLZ sells at a price-to-earnings ratio of 25, which is in-line with the sector. So even though its management acts like it's a momentum company, the stock is not as frothy as one. Johnson & Johnson (JNJ)Source: Shutterstock Johnson & Johnson has been a proven performer for over a century, so the effects of last year's headline over the talcum lawsuits will inevitably fade. This is not to minimize the issue and its effects on those who suffered, but JNJ stock will recover from it. Owning JNJ stock now offers the opportunity to ride the snapback rally. * 7 Dividend Stocks to Buy Today JNJ is not screaming cheap, but the macroeconomic correction from last year and JNJ-specific headlines have shaken the weak hands from the stock. This makes for a strong base going forward. And the sellers will be less likely to panic at the first sign of weakness. Consumer Staples Select Sector SPDR ETFEven though buying the XLP is similar to investing individually in MDLZ or JNJ, doing so diffuses the risks of individual headlines. There are heavyweight tickers in the XLP, but none that would bring down the whole exchange-traded fund. They do, however, trade in unison, so that risk remains.But from here, the XLP chart looks bullish. Even though it is lagging the SPY in its bounce off the December lows, the XLP is setting higher lows and has a breakout neckline just above current levels. If the bulls can breakout of $55 per share they can overshoot to target the all-time highs from November. There will be resistance along the way, especially around $56 per share … this is where the real selling began last year.So why expect a move now?The XLP chart has set higher lows and lower highs, thereby bringing it to a point. These usually are precursors to big moves because the energy needs to disperse quickly. So if the stock market, in general, continues this breakout, the XLP will eventually finish its own breakout upwards.Nicolas Chahine is the managing director of SellSpreads.com. As of this writing, he did not hold a position in any of the aforementioned securities. You can follow him as @racernic on Twitter and Stocktwits. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 of the Best Stocks to Buy Under $10 * 7 Single-Digit P/E Stocks With Massive Upside * 7 Best Quantum Computing Stocks Trading Today Compare Brokers The post 3 Consumer Staples Stocks to Trade in 2019 appeared first on InvestorPlace.

  • Are Hedge Funds Right About Berkshire Hathaway Inc. (BRK-B)?
    Insider Monkey2 days ago

    Are Hedge Funds Right About Berkshire Hathaway Inc. (BRK-B)?

    Reputable billionaire investors such as Jim Simons, Cliff Asness and David Loeb generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won't accept your savings unless you commit at least $5 million) by pinpointing winning […]

  • Investing.com2 days ago

    UnitedHealth Shares Finding Their Mojo Again

    Investing.com - UnitedHealth Group (NYSE:UNH) has been a big reason why the Dow has held its own lately.

  • The Zacks Analyst Blog Highlights: Pfizer, Roche, Merck, Allergan and J&J
    Zacks2 days ago

    The Zacks Analyst Blog Highlights: Pfizer, Roche, Merck, Allergan and J&J

    The Zacks Analyst Blog Highlights: Pfizer, Roche, Merck, Allergan and J&J

  • 5 Recession-Proof Stocks
    Motley Fool5 days ago

    5 Recession-Proof Stocks

    Almost no one is thinking about the fifth company, and therein lies opportunity.

  • TheStreet.com5 days ago

    The Rally in Johnson & Johnson Looks Like it has Run Its Course

    In Thursday night's Mad Money program, Jim Cramer told viewers that there are still plenty of opportunities for individuals to buy individual stocks. Cramer identified five risks that investors need to consider. In this Japanese candlestick chart of JNJ, below, we can see the price action of the last six months (only looking at six months of candles allows us to see the patterns better).

  • Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others
    Zacks5 days ago

    Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others

    Regulatory updates from J&J (JNJ), Merck (MRK), Roche (RHHBY), Pfizer (PFE) and others.

  • Company News For Mar 15, 2019
    Zacks5 days ago

    Company News For Mar 15, 2019

    Companies In The News Are: BA, DG, JNJ, WAGE

  • J&J Seeks Approval for Darzalex in Expanded Patient Group
    Zacks5 days ago

    J&J Seeks Approval for Darzalex in Expanded Patient Group

    J&J (JNJ) files sBLA seeking approval for Darzalex combination regimen in newly- diagnosed, transplant ineligible multiple myeloma patient population.

  • Jabil Circuit Inc (JBL) Q2 2019 Earnings Conference Call Transcript
    Motley Fool6 days ago

    Jabil Circuit Inc (JBL) Q2 2019 Earnings Conference Call Transcript

    JBL earnings call for the period ending February 28, 2019.

  • TheStreet.com6 days ago

    The Perils of Stock Investing: Cramer's 'Mad Money' Recap (Thursday 3/14/19)

    Making money in the stock market isn't easy, Jim Cramer admitted to his Mad Money viewers on the 14th anniversary of the show. For Thursday's session, Cramer identified five risks that investors need to consider.

  • TheStreet.com6 days ago

    Jim Cramer: 5 Examples Show Why Stock Investing Is So Difficult

    Consider these five, right in front of you on this one day, so you get the perils of stock ownership and know how to handle them when they occur.

  • CNBC6 days ago

    Cramer: Five 'perils' of investing in individual stocks

    Jim Cramer takes a look at some of the biggest headlines of the week that have rocked stocks on the market.

  • Barrons.com6 days ago

    3 More Outstanding Funds for Dividend Investors

    The Barron’s Income column has presented the five top-performing dividend ETFs and the five leading actively managed dividend mutual funds over the past five years. Here are three more strongly performing actively managed dividend funds.

  • Reuters6 days ago

    US STOCKS-Wall St near flat as trade deal outlook uncertain

    U.S. stocks were little changed in late afternoon trading on Thursday amid uncertainty over when a trade deal between the United States and China would be reached. President Donald Trump said the United States was doing very well in trade talks with China, but could not say whether a final deal would be reached. Trump and Chinese President Xi Jinping had been expected to hold a summit at the president's Mar-a-Lago property in Florida later this month, but no date has been set for a meeting.

  • American City Business Journals6 days ago

    $18M Johnson & Johnson facility adds strength to Lake Nona's profile

    Gloria Caulfield believes Johnson & Johnson will help boost the health of Lake Nona with the new $18 million headquarters of its Human Performance Institute. The vice president of strategic alliances for Lake Nona developer Tavistock Development Co. LLC said the new 31,500-square-foot Johnson & Johnson Human Performance Institute complex provides another reason for executives to be drawn to the area. The institute — which relocated from a smaller building farther north in Lake Nona — now has a larger space to teach and host participants in its classes providing lessons on how to prevent corporate burnout and more.